RESMED INC RMD

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.

Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a mask, to prevent collapse of the upper airway during sleep. Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients' long-term adherence to and satisfaction with their therapy.

Last close 252.86 2026-10-23
Market cap $36.48B 2026-06-30 share count
52-week range 180.26 - 277.67

Valuation FY2026 figures against the last close

P/S6.5x
P/E24.2x
P/FCF22.1x
EV/EBITDA17.1x
Dividend yield1.0%
Diluted EPS10.43

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Rest of the World
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2026 United States, FY2026: 3.6B (63.0%) 63% United States Rest of the World, FY2026: 2.1B (37.0%) 37% Rest of the World FY2025 United States, FY2025: 3.3B (63.8%) 64% Rest of the World, FY2025: 1.9B (36.2%) 36% FY2024 United States, FY2024: 3B (63.6%) 64% Rest of the World, FY2024: 1.7B (36.4%) 36%
Region FY2026FY2025FY2024
United States $3.56B $3.29B $2.98B
Rest of the World $2.09B $1.86B $1.71B

As the company reported it, from the “Segment Information - Schedule of Revenue by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $5.65B$5.15B$4.69B$4.22B$3.58B$3.20B$2.96B$2.61B$2.34B$2.07B
Cost of revenue $2.20B$2.09B$2.03B$1.87B$1.55B$1.36B$1.24B$1.11B$1.01B$865.0M
Gross profit $3.45B$3.05B$2.66B$2.36B$2.02B$1.84B$1.72B$1.49B$1.33B$1.20B
R&D $378.3M$331.3M$307.5M$287.6M$253.6M$225.3M$201.9M$180.7M$155.1M$144.5M
SG&A $1.12B$993.0M$917.1M$874.0M$737.5M$670.4M$676.7M$645.0M$600.4M$554.0M
Total operating expenses $1.57B$1.37B$1.34B$1.22B$1.02B$935.4M$908.1M$914.8M$793.1M$775.9M
Operating income $1.89B$1.69B$1.32B$1.13B$1.00B$903.7M$809.7M$579.3M$541.8M$425.8M
Interest expense ———$47.4M$22.3M$23.6M$39.4M$36.2M$28.4M$28.2M
Pre-tax income $1.92B$1.68B$1.26B$1.10B$960.5M$883.7M$733.1M$518.8M$521.3M$418.7M
Income tax $396.1M$276.8M$243.8M$204.1M$181.0M$409.2M$111.4M$114.3M$205.7M$76.5M
Net income $1.52B$1.40B$1.02B$897.6M$779.4M$474.5M$621.7M$404.6M$315.6M$342.3M
EPS, basic 10.479.556.946.125.343.274.312.832.212.42
EPS, diluted 10.439.516.926.095.303.244.272.802.192.40
Shares, diluted (wtd. avg.) 146.1M147.3M147.6M147.5M147.0M146.5M145.7M144.5M144.0M142.5M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $1.47B$1.21B$238.4M$227.9M$273.7M$295.3M$463.2M$147.1M$188.7M$821.9M
Receivables $1.04B$939.5M$837.3M$704.9M$576.0M$614.3M$474.6M$528.5M$483.7M$450.5M
Inventory $945.8M$927.7M$822.2M$998.0M$743.9M$457.0M$416.9M$349.6M$268.7M$268.3M
Total current assets $4.32B$3.51B$2.36B$2.37B$1.93B$1.57B$1.52B$1.15B$1.07B$1.64B
Property, plant and equipment $581.8M$550.8M$548.0M$537.9M$498.2M$463.5M$417.3M$387.5M$386.6M$394.2M
Goodwill $2.91B$3.05B$2.84B$2.77B$1.94B$1.93B$1.89B$1.86B$1.07B$1.06B
Other intangibles $452.7M$464.9M$485.9M$552.3M$345.9M$392.6M$448.2M$522.0M$215.2M$261.8M
Total assets $8.97B$8.17B$6.87B$6.75B$5.10B$4.73B$4.59B$4.11B$3.06B$3.47B
Accounts payable $308.9M$278.2M$237.7M$150.8M$159.2M$138.0M$135.8M$115.7M$92.7M$92.8M
Short-term debt $259.9M$9.9M$9.9M$9.9M$9.9M$12.0M$12.0M$12.0M$11.5M—
Total current liabilities $1.40B$1.02B$910.7M$758.5M$689.3M$911.8M$602.8M$556.0M$511.2M$360.1M
Long-term debt $399.4M$658.4M$697.3M$1.43B$765.3M$643.4M$1.16B$1.26B$270.0M$1.08B
Total liabilities $2.38B$2.21B$2.01B$2.62B$1.74B$1.84B$2.09B$2.04B$1.00B$1.51B
Retained earnings $7.26B$6.08B$4.99B$4.25B$3.61B$3.08B$2.83B$2.44B$2.43B$2.32B
Total equity $6.59B$5.97B$4.86B$4.13B$3.36B$2.89B$2.50B$2.07B$2.06B$1.96B

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $1.81B$1.75B$1.40B$693.3M$351.1M$736.7M$802.3M$459.1M$505.0M$414.1M
Depreciation and amortisation $201.3M$198.5M$176.9M$165.2M$159.6M$156.8M$154.8M$150.8M$120.0M$112.2M
Stock-based compensation $104.3M$91.7M$80.2M$71.1M$65.3M$63.9M$57.6M$52.1M$48.4M$45.9M
Capital expenditure $156.3M$89.9M$99.5M$119.7M$134.8M$102.7M$95.3M$68.7M$62.6M$62.2M
Investing cash flow -$545.2M-$200.0M-$269.8M-$1.16B-$229.9M-$158.5M-$179.9M-$1.08B-$101.8M-$81.9M
Financing cash flow -$1.01B-$606.3M-$1.12B$422.9M-$128.4M-$764.6M-$317.3M$580.6M-$1.03B-$262.9M
Dividends paid $349.7M$310.9M$282.3M$258.3M$245.3M$226.7M$225.1M$211.7M$199.5M$186.3M
Buybacks $700.0M$300.0M$150.0M$0$0——$22.8M$53.8M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000943819-26-000047.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B Revenue, FY2017: 2.1B Gross profit, FY2017: 1.2B Net income, FY2017: 342.3M Revenue, FY2018: 2.3B Gross profit, FY2018: 1.3B Net income, FY2018: 315.6M Revenue, FY2019: 2.6B Gross profit, FY2019: 1.5B Net income, FY2019: 404.6M Revenue, FY2020: 3B Gross profit, FY2020: 1.7B Net income, FY2020: 621.7M Revenue, FY2021: 3.2B Gross profit, FY2021: 1.8B Net income, FY2021: 474.5M Revenue, FY2022: 3.6B Gross profit, FY2022: 2B Net income, FY2022: 779.4M Revenue, FY2023: 4.2B Gross profit, FY2023: 2.4B Net income, FY2023: 897.6M Revenue, FY2024: 4.7B Gross profit, FY2024: 2.7B Net income, FY2024: 1B Revenue, FY2025: 5.1B Gross profit, FY2025: 3.1B Net income, FY2025: 1.4B Revenue, FY2026: 5.7B Gross profit, FY2026: 3.5B Net income, FY2026: 1.5B FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $2.07B $2.34B $2.61B $2.96B $3.20B $3.58B $4.22B $4.69B $5.15B $5.65B
Gross profit $1.20B $1.33B $1.49B $1.72B $1.84B $2.02B $2.36B $2.66B $3.05B $3.45B
Net income $342.3M $315.6M $404.6M $621.7M $474.5M $779.4M $897.6M $1.02B $1.40B $1.52B

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event Item 8.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%
SOLV Solventum Corp $14.54B 9.6x 0.9%